Reset Map4 Results
Fuchunjiang Rd No. 188, Gaoxin District, Suzhou, Jiangsu, 215163 ChinaDIMA Biotechnology LLC is a leading biotechnology company specializing in preclinical research and development solutions for the biopharmaceutical industry. We focus on accelerating early-stage drug discovery by providing a comprehensive portfolio of pre-designed, sequence-verified, and functionally validated antibody molecules tailored to the evolving needs of BioPharma companies. With over 5,000 lead antibody molecules targeting approximately 500 druggable targets, our rapidly expanding library enables faster candidate selection and streamlined R&D timelines. We are actively working toward developing lead antibodies for all potential therapeutic targets, reinforcing our commitment to supporting innovation and efficiency in antibody-based drug development. Our technological edge lies in the continued optimization of proprietary platforms that span the full antibody discovery and development pipeline: DiMPro™ Membrane Protein Platform: We are experts in expressing and purifying membrane proteins using mammalian systems. Our inventory includes over 1,000 functional proteins, featuring more than 500 active full-length multi-pass membrane proteins, such as GPCRs and ion channels. We offer five proven expression formats: Membrane Nanoparticles (MNP), Virus-Like Particles (VLP), Exosomes (EXO), Detergent-based extraction, and Nanodiscs. DIMA mAb™ Single B Cell Antibody Discovery Platform: This high-throughput discovery platform enables the rapid generation of over 10,000 positive antibody hits within a month. It efficiently delivers diverse, fully sequence-defined monoclonal antibodies with high functional relevance. DiLibrary™ Mammalian Display Antibody Engineering Platform: Our proprietary engineering system supports key antibody optimization processes such as humanization and affinity maturation. Antibodies developed using DiLibrary™ exhibit enhanced developability compared to traditional phage or yeast display methods. DiAssay™ Antibody Evaluation Platform: This platform supports customized screening and functional assessment, enabling identification of optimal hit molecules for a range of therapeutic modalities, including Bispecific Antibodies (BsAbs), Antibody-Drug Conjugates (ADCs), and CAR-T therapies. At DIMA Biotechnology, we are driven by a mission to empower the BioPharma community with high-quality, innovative solutions that shorten development cycles and accelerate the creation of transformative therapies.
Wuhan institute of Biotechnology B7, No.666 Gaoxin Road, Wuhan, Hubei , 430074 ChinaDIMA Biotechnology LLC is a leading biotechnology company specializing in preclinical research and development solutions for the biopharmaceutical industry. We focus on accelerating early-stage drug discovery by providing a comprehensive portfolio of pre-designed, sequence-verified, and functionally validated antibody molecules tailored to the evolving needs of BioPharma companies. With over 5,000 lead antibody molecules targeting approximately 500 druggable targets, our rapidly expanding library enables faster candidate selection and streamlined R&D timelines. We are actively working toward developing lead antibodies for all potential therapeutic targets, reinforcing our commitment to supporting innovation and efficiency in antibody-based drug development. Our technological edge lies in the continued optimization of proprietary platforms that span the full antibody discovery and development pipeline: DiMPro™ Membrane Protein Platform: We are experts in expressing and purifying membrane proteins using mammalian systems. Our inventory includes over 1,000 functional proteins, featuring more than 500 active full-length multi-pass membrane proteins, such as GPCRs and ion channels. We offer five proven expression formats: Membrane Nanoparticles (MNP), Virus-Like Particles (VLP), Exosomes (EXO), Detergent-based extraction, and Nanodiscs. DIMA mAb™ Single B Cell Antibody Discovery Platform: This high-throughput discovery platform enables the rapid generation of over 10,000 positive antibody hits within a month. It efficiently delivers diverse, fully sequence-defined monoclonal antibodies with high functional relevance. DiLibrary™ Mammalian Display Antibody Engineering Platform: Our proprietary engineering system supports key antibody optimization processes such as humanization and affinity maturation. Antibodies developed using DiLibrary™ exhibit enhanced developability compared to traditional phage or yeast display methods. DiAssay™ Antibody Evaluation Platform: This platform supports customized screening and functional assessment, enabling identification of optimal hit molecules for a range of therapeutic modalities, including Bispecific Antibodies (BsAbs), Antibody-Drug Conjugates (ADCs), and CAR-T therapies. At DIMA Biotechnology, we are driven by a mission to empower the BioPharma community with high-quality, innovative solutions that shorten development cycles and accelerate the creation of transformative therapies.
14644 Devereaux Ter GAITHERSBURG, MD, 20878 United StatesDIMA Biotechnology LLC is a leading biotechnology company specializing in preclinical research and development solutions for the biopharmaceutical industry. We focus on accelerating early-stage drug discovery by providing a comprehensive portfolio of pre-designed, sequence-verified, and functionally validated antibody molecules tailored to the evolving needs of BioPharma companies. With over 5,000 lead antibody molecules targeting approximately 500 druggable targets, our rapidly expanding library enables faster candidate selection and streamlined R&D timelines. We are actively working toward developing lead antibodies for all potential therapeutic targets, reinforcing our commitment to supporting innovation and efficiency in antibody-based drug development. Our technological edge lies in the continued optimization of proprietary platforms that span the full antibody discovery and development pipeline: DiMPro™ Membrane Protein Platform: We are experts in expressing and purifying membrane proteins using mammalian systems. Our inventory includes over 1,000 functional proteins, featuring more than 500 active full-length multi-pass membrane proteins, such as GPCRs and ion channels. We offer five proven expression formats: Membrane Nanoparticles (MNP), Virus-Like Particles (VLP), Exosomes (EXO), Detergent-based extraction, and Nanodiscs. DIMA mAb™ Single B Cell Antibody Discovery Platform: This high-throughput discovery platform enables the rapid generation of over 10,000 positive antibody hits within a month. It efficiently delivers diverse, fully sequence-defined monoclonal antibodies with high functional relevance. DiLibrary™ Mammalian Display Antibody Engineering Platform: Our proprietary engineering system supports key antibody optimization processes such as humanization and affinity maturation. Antibodies developed using DiLibrary™ exhibit enhanced developability compared to traditional phage or yeast display methods. DiAssay™ Antibody Evaluation Platform: This platform supports customized screening and functional assessment, enabling identification of optimal hit molecules for a range of therapeutic modalities, including Bispecific Antibodies (BsAbs), Antibody-Drug Conjugates (ADCs), and CAR-T therapies. At DIMA Biotechnology, we are driven by a mission to empower the BioPharma community with high-quality, innovative solutions that shorten development cycles and accelerate the creation of transformative therapies.
Medical Center Drive Rockville , MD, 20850 United StatesDIMA Biotechnology LLC is a leading biotechnology company specializing in preclinical research and development solutions for the biopharmaceutical industry. We focus on accelerating early-stage drug discovery by providing a comprehensive portfolio of pre-designed, sequence-verified, and functionally validated antibody molecules tailored to the evolving needs of BioPharma companies. With over 5,000 lead antibody molecules targeting approximately 500 druggable targets, our rapidly expanding library enables faster candidate selection and streamlined R&D timelines. We are actively working toward developing lead antibodies for all potential therapeutic targets, reinforcing our commitment to supporting innovation and efficiency in antibody-based drug development. Our technological edge lies in the continued optimization of proprietary platforms that span the full antibody discovery and development pipeline: DiMPro™ Membrane Protein Platform: We are experts in expressing and purifying membrane proteins using mammalian systems. Our inventory includes over 1,000 functional proteins, featuring more than 500 active full-length multi-pass membrane proteins, such as GPCRs and ion channels. We offer five proven expression formats: Membrane Nanoparticles (MNP), Virus-Like Particles (VLP), Exosomes (EXO), Detergent-based extraction, and Nanodiscs. DIMA mAb™ Single B Cell Antibody Discovery Platform: This high-throughput discovery platform enables the rapid generation of over 10,000 positive antibody hits within a month. It efficiently delivers diverse, fully sequence-defined monoclonal antibodies with high functional relevance. DiLibrary™ Mammalian Display Antibody Engineering Platform: Our proprietary engineering system supports key antibody optimization processes such as humanization and affinity maturation. Antibodies developed using DiLibrary™ exhibit enhanced developability compared to traditional phage or yeast display methods. DiAssay™ Antibody Evaluation Platform: This platform supports customized screening and functional assessment, enabling identification of optimal hit molecules for a range of therapeutic modalities, including Bispecific Antibodies (BsAbs), Antibody-Drug Conjugates (ADCs), and CAR-T therapies. At DIMA Biotechnology, we are driven by a mission to empower the BioPharma community with high-quality, innovative solutions that shorten development cycles and accelerate the creation of transformative therapies.
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.